Semaglutide helps reduce risk of heart attack, stroke in people without diabetes, study finds - ABC News

Semaglutide is the main ingredient in Wegovy and Ozempic. A recent study found it may help reduce the risk of heart attack and stroke in people without diabetes.
Semaglutide is the main ingredient in medications including Wegovy and Ozempic.
ABC News’ Dr. Jennifer Ashton explains a new study in the New England Journal of Medicine that shows a reduction in heart attacks, strokes and death in overweight or obese participants who took semaglutide.

How medications like Ozempic are revolutionizing the weight loss industry

Semaglutide helps reduce risk of heart attack, stroke in people without diabetes, study finds - ABC News

Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6

Treatment algorithm in diabetic patients with a history of stroke

Remote Health Solutions

Semaglutide helps reduce risk of heart attack, stroke in people without diabetes, study finds - ABC News

Eli Lilly, Novo Nordisk stocks soar after weight-loss drug trial boosts outlook [Video]

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee

Novo Nordisk's anti-obesity drug Wegovy not only helped people lose

Frontiers The Evolving Understanding and Approach to Residual Cardiovascular Risk Management

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial - The Lancet Diabetes